Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928031 · ClinicalTrials.gov registry record
Long-term Data Collection for Subjects in MDX-010 Studies
A clinical trial of Metastatic Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 160
- Enrollment target
- 11
- Study locations
NCT00928031: Completed study of Metastatic Melanoma, sponsored by Bristol-Myers Squibb.
NCT00928031 is a study of Metastatic Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 160 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928031, a study of Metastatic Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
- 11
- Study locations
Study Summary
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
Conditions Studied
Study Locations (11)
California
- Pacific Shores Medical Group - Long Beach
- The Angeles Clinic and Research Institute - Los Angeles
- USC Norris Cancer Center - Los Angeles
Arizona
- Arizona Cancer Center - Tuscon
Florida
- University of Miami Sylvester Cancer Center - Miami
Indiana
- St. Francis Research Foundation - Beech Grove
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- NYU Cancer Institute - New York
North Carolina
- Carolinas Cancer Care - Charlotte
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
What the finished NCT00928031 record still lists
NCT00928031 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT00928031 lists 11 locations in 9 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT00928031 about?
NCT00928031 is a clinical study titled "Long-term Data Collection for Subjects in MDX-010 Studies". The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
What is the current status of trial NCT00928031?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2007-06. Estimated completion is 2009-04.
What conditions does trial NCT00928031 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
Who is sponsoring clinical trial NCT00928031?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00928031 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00928031's enrollment target sits among peer trials
160 12th of 91 higher than 79 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia